source
- Supreme Court rules generic Vascepa copy does not infringe patents, boosting skinny-label pathwayThe U.S. Supreme Court issued a decision that Hikma Pharmaceuticals’ generic version of Amarin’s heart drug Vascepa does not infringe the brand’s patents. The ruling clarified that the generic make…
- ADC Therapeutics shares plunge as Phase 3 trial of Zynlonta shows high death rate despite efficacy gainADC Therapeutics reported Phase 3 data for Zynlonta combined with rituximab in a hard-to-treat blood cancer. The trial met its primary endpoint by extending progression-free survival versus standar…